Inspire Medical Systems, Inc. (NYSE:INSP) Given Average Rating of “Hold” by Analysts

Inspire Medical Systems, Inc. (NYSE:INSP) has been assigned a consensus rating of “Hold” from the nineteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, twelve have assigned a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $66.1875.

INSP has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Inspire Medical Systems in a research report on Monday, August 3rd. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Bank of America cut Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective for the company. in a research note on Friday, May 22nd. Summit Redstone set a $39.00 price objective on Inspire Medical Systems in a report on Friday, May 22nd. Finally, Stifel Nicolaus set a $75.00 target price on Inspire Medical Systems in a research note on Tuesday, August 4th.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $57.26 on Wednesday. Inspire Medical Systems has a one year low of $38.91 and a one year high of $147.03. The company has a 50 day moving average of $49.38 and a 200-day moving average of $53.27. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of 12.39, a P/E/G ratio of 4.34 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. During the same period in the previous year, the firm posted $0.45 earnings per share. Inspire Medical Systems’s revenue for the quarter was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities research analysts anticipate that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Insider Activity at Inspire Medical Systems

In related news, insider Jason P. Kelly sold 963 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider directly owned 18,985 shares in the company, valued at $1,130,556.75. This trade represents a 4.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Daiwa Securities Group Inc. lifted its stake in Inspire Medical Systems by 38.7% in the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after buying an additional 130 shares during the period. State of Wyoming grew its position in shares of Inspire Medical Systems by 31.5% during the 4th quarter. State of Wyoming now owns 731 shares of the company’s stock worth $67,000 after buying an additional 175 shares during the period. Smartleaf Asset Management LLC increased its stake in shares of Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares in the last quarter. Apollon Wealth Management LLC increased its stake in shares of Inspire Medical Systems by 5.6% in the 1st quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock valued at $206,000 after acquiring an additional 212 shares in the last quarter. Finally, Blair William & Co. IL lifted its position in shares of Inspire Medical Systems by 5.1% during the 3rd quarter. Blair William & Co. IL now owns 4,865 shares of the company’s stock valued at $361,000 after acquiring an additional 234 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.